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njured axons in mammalian peripheral nerves often re-
generate successfully over long distances, in contrast to
axons in the brain and spinal cord (CNS). Neurite
growth-inhibitory proteins, including the recently cloned
membrane protein Nogo-A, are enriched in the CNS, in
particular in myelin. Nogo-A is not detectable in peripheral
nerve myelin. Using regulated transgenic expression of
Î
 
Nogo-A in peripheral nerve Schwann cells, we show that
axonal regeneration and functional recovery are impaired
after a sciatic nerve crush. Nogo-A thus overrides the
growth-permissive and -promoting effects of the lesioned
peripheral nerve, demonstrating its in vivo potency as an
inhibitor of axonal regeneration.
 
Introduction
 
Lesioned central axons successfully regenerate over long
distances into peripheral nerves transplanted into the brain
or spinal cord (Bray et al., 1987), whereas cultured peripheral
axons grown under optimal conditions strictly refuse to invade
explants of adult CNS tissue, in particular CNS white matter
(Schwab and Thoenen, 1985). This observation suggested
for the first time the presence of specific neurite growth-
inhibitory factors in the adult CNS (Schwab and Thoenen,
1985; Caroni and Schwab, 1988). Various bioassays pointed
to a high molecular weight membrane protein (NI-250, IN-1
antigen) later purified and identified as Nogo-A (Caroni and
Schwab, 1988; Chen et al., 2000). Subsequently, several
proteins and proteoglycans with neurite growth-inhibitory
activity were identified in CNS myelin, including myelin-
associated glycoprotein and chondroitin sulfate proteoglycans
(Qiu et al., 2000).
To investigate in vivo the inhibitory characteristics of
Nogo-A, we generated transgenic mice expressing the rat
 
nogo A
 
 gene under the inducible control of the Schwann
cell–specific 
 
P0
 
 promoter (unpublished data). P0 is the major
structural protein of peripheral myelin, and previous studies
demonstrated the usefulness and specificity of the 
 
P0
 
 pro-
moter for transgene expression in Schwann cells (Messing et
al., 1992)
 
.
 
Results and discussion
 
Transgenic mice were generated in which a myc-tagged 
 
nogo
A
 
 gene was expressed postnatally using the inducible rtTA2
system (Urlinger et al., 2000) under the control of a fusion
promoter (
 
P0Cx
 
). The 
 
P0Cx
 
 fusion promoter is composed
of Schwann cell–specific regulatory elements of the 1.1-kb
rat 
 
P0
 
 promoter and of the human connexin 32 gene (
 
Cx32
 
;
Abel et al., 1999). The 1.1-kb 
 
P0
 
 promoter alone was often
used, but transgene expression was inconsistent (Feltri et al.,
1999). For high expression in mice, a Schwann cell–specific
intron from the 
 
Cx32
 
 gene was added after the 
 
P0
 
 promoter.
By inducing the expression of 
 
nogo A
 
 only after birth, we
 
could avoid possible effects of Nogo-A protein on the develop-
ment of the PNS. Transgenic lines were made that express
the rtTA2 or the responder, a bidirectional tetO promoter
(pBI-3 construct; Baron et al., 1995) directing 
 
nogo A
 
 and
 
lacZ
 
 transcription (Fig. 1 A). rtTA2 is a second generation
rtTA system, which requires low doses of doxycycline for
activation and has almost no background activity (Urlinger
et al., 2000). To test the pBI-3-
 
nogo A
 
, we transfected it into
HeLa cells stably transfected with a tTA construct, which
activates transcription from tetO promoters in the absence
of doxycycline (Gossen and Bujard, 1992). The cells expressed
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both 
 
 
 
-galactosidase and 
 
nogo A
 
 when doxycycline was
omitted from the medium (Fig. 1 B).
Several founder mouse lines were obtained from pBI-3-
 
nogo A
 
 and 
 
P0Cx
 
-rtTA2 constructs and the strongest ex-
pressing lines were used. Single transgenic mice were mated
to produce the Nogo-A–expressing double transgenic mice.
The system was not leaky because X-Gal staining was only
found in sciatic nerves of doxycycline-treated double trans-
genic mice. Nogo-A expression was induced at birth by feed-
ing the mothers with doxycycline. The efficiency and speci-
ficity of the promoter was assessed in three ways. (1) X-Gal
staining of the sciatic nerve showed large numbers of labeled
cells (Fig. 2 A). No labeling was present in the spinal cord
(unpublished data). Immunohistochemistry for (2) Nogo-A
and (3) myc showed Nogo-A– and myc-positive cells and
myelin structures in sciatic nerves exclusively of the double
transgenic animals under doxycycline. Nogo-A, colocalized
with the specific marker of Schwann cells S-100, was found
in the Schwann cell bodies and in the outer and inner loops
of the myelin, similar to that described for Nogo-A in oligo-
dendrocytes and in myelin of the CNS (Fig. 2 C) (Huber et
al., 2002). Two Nogo-A transgenic mouse lines, Tg11 and
Tg16, were selected and compared using the X-Gal staining;
the mice of the Tg11 line showed stronger staining than
those from Tg16 (Fig. 2 A). At least 20% of the Schwann
cells in line Tg16 and 
 
 
 
45% of the Schwann cells in line
Tg11 expressed a high level of the transgene (Fig. 2, B and
C). The overall level of expression of the transgene in the sci-
atic nerve (Tg11) was about one third that of endogenous
Nogo-A in the optic nerve (CNS) of the same animals (un-
published data).
 
Modifying the components of peripheral myelin could
disturb the myelin structure (Siconolfi and Seeds, 2001). At
the light and electron microscopic level, the Schwann cells,
axons, and myelin of Nogo-A–expressing peripheral nerves
appeared normal (Fig. 3, A–C). The transgenic mice devel-
oped normally and their gait was normal, as indicated by
footprint analysis (overlapping footprint patterns for control
and transgenic mice). Motor coordination and balance were
tested on the rotarod (Fig. 3 D) at 10 wk of age and no defi-
cits were recorded in transgenic mice. The animals were also
indistinguishable from control littermates (single transgenics
for 
 
P0-rtTA
 
 or 
 
nogo A
 
/
 
lacZ
 
 only or wild types), using the
narrow beam test (unpublished data).
To test the influence of Nogo-A expression on axonal re-
generation in the PNS, freeze-crush lesions of the sciatic nerve
on 8–12-wk-old mice were performed. All motor (and pre-
sumably sensory) axons were lesioned, as indicated by the fail-
ure of Fluorogold tracer to retrogradely label motoneurons
when applied 0–2 d after the crush (
 
n
 
 
 
 
 
 12; unpublished
data). Neurological recovery was analyzed by the sciatic func-
tional index (SFI)* (de Medinaceli et al., 1982), which char-
acterizes hindlimb use and foot and toe positions, and by the
toe pinch reflex (Siconolfi and Seeds, 2001), a simple sensory
motor reflex (Fig. 4). The number of successfully regenerating
motoneuron axons was then determined by a retrograde trac-
ing and a direct immunostaining of the axons distal to the le-
sion (Sagot et al., 1998). For all behavioral tasks and opera-
tions, double transgenic mice (Tg) and control littermates
Figure 1. Regulated expression system for the 
nogo A transgene, and in vitro expression of 
 -galactosidase and nogo A–myc. (A) Strategy 
used to obtain Schwann cell–specific doxycycline-
regulated transgene expression. Transgenic mice 
carrying the rtTA2 gene driven by the rat 1.1-kb P0 
promoter fused to 320 bp of the connexin 32 
fragment were crossed with mice carrying the 
bidirectional tetO promoter inducing nogo A–myc 
and lacZ transcription when doxycycline is added. 
(B) TetO-nogo A/LacZ transfected into tTA HeLa 
cells (expression is activated by removal of 
doxycycline in the tTA system) showed no X-Gal, 
myc, or Nogo-A staining when doxycycline was in 
the medium ( Dox). When doxycycline was 
withdrawn ( Dox), the cells showed expression of 
X-Gal, myc, and Nogo-A. Bar, 25  m.
 
*Abbreviations used in this paper: PFA, paraformaldehyde; SFI, sciatic
functional index. 
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(Ctr), having no transgene or a single transgene (
 
P0Cx-rtTA2
 
or 
 
nogo A
 
/
 
lacZ
 
 only), were used. All animals received doxycy-
cline from birth until the end of the experiments.
The SFI evaluates crucial aspects of locomotion involving
recovery of hindlimb sensory and motor function. Nonle-
sioned animals have an SFI of zero (
 
 
 
10). Both transgenic
Figure 2. In vivo expression of the transgene in the sciatic 
nerve. (A) X-Gal staining of a sciatic nerve whole mount of a 
3-mo-old double transgenic mouse of Tg16 results in blue-
labeled Schwann cell nuclei (nuclear localization signal 
preceding lacZ). Cross sections of 7-wk-old mouse sciatic nerves 
show more X-Gal staining in the Schwann cells of Tg11 than of 
Tg16. (B) Colocalization of myc with Nogo-A protein. At low 
magnification, cross sections of P25 sciatic nerves of control mice 
(Ctrl) show weak, mostly axonal (insert, thin arrow) staining of 
Nogo-A and no myc staining. In the transgenic animal (Tg16) the 
Nogo-A level is higher and Nogo-A is colocalized with myc 
(merged). The insert shows Nogo-A in axons and additionally in 
the outer myelin loops (arrowheads). The immunological signals 
for Nogo-A were stronger than those for the myc tag in this study. 
(C) Colocalization of myc with the Schwann cell marker S-100 
and of myc with Nogo-A. In double immunolabeled sections of 
Tg11, S-100/myc (left) and Nogo-A/myc (right) are colocalized in 
the Schwann cell bodies (arrows), as well as in the outer (closed 
arrowheads) and inner (open arrowhead) loops of myelin, similar 
to the localization of Nogo-A in oligodendrocytes and CNS 
myelin (Huber et al., 2002). Bars: (A and B) 60  m; (C) 20  m.
Figure 3. Nogo-A transgenic animals have a normal sciatic nerve 
histology and normal motor behavior before lesion. (A) Semi-thin 
sections of sciatic nerve from a 7-wk-old control (Ctrl) mouse and 
an age-matched Nogo-A transgenic (Tg11) stained with toluidine 
blue show normally myelinated large and small caliber axons. 
Schwann cells (arrows) are present and normal. (B) Electron 
micrographs show no detectable cytoplasmic abnormalities in 
myelinating and nonmyelinating Schwann cells in Ctrl and Tg11. 
(C) No differences were seen for the myelin spacing of Ctrl and 
Tg11 Schwann cells. (D) Behavioral assessment. 10-wk-old mice 
(Ctrl, Tg11, and Tg16) were tested on a rotating rod (rotarod) on two 
consecutive days. No differences were found in the latency to fall 
off from the rotarod, neither in the acceleration test (left) nor in the 
fatigue test (right). The means ( SEM) of control (Ctrl; n   23), line 
11 (Tg11; n   7), and line 16 mice (Tg16; n   13) are presented. 
Bars: (A) 12  m; (B) 1.2  m; (C) 0.25  m. 
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and control mice showed normal SFI values before the le-
sion. Sciatic nerve crush produced a massive disability mani-
fested by a negative SFI that returned to zero as the sciatic
axons regenerated. Control mice recovered with a typical
time course of 2–3 wk (Fig. 4 A), in line with published data
(Chen and Bisby, 1993). For the two Nogo-A transgenic
lines, recovery was significantly delayed. Tg11 mice showed
an overall poor recovery with large deficits persisting 30 d af-
ter the lesion. SFI recovery of Tg16 mice was better than of
Tg11, but still significantly slower and less complete than in
the control mice (Fig. 4 A).
In the toe pinch reflex
 
,
 
 before sciatic nerve crush, all mice
showed equal sensitivity; a pinch of toe 3, 4, or 5 (tested sep-
arately) reliably induced a rapid retraction of the leg (digits 1
and 2 are innervated by the saphenous nerve and were there-
fore not tested). After the crush, the response was totally
abolished in all animals. The time taken for the injured
hindlimb to show any degree of a response to the stimulus
was noted. Digit function recovery occurred in a medial to
lateral direction in all mice (Fig. 4 B). The recovery was
monitored over 30 d, and in many of the transgenic mice
the sensitivity of the last two digits did not appear. The toe
pinch reflex values from those animals were extrapolated
from the recovery curve. The percentage of animals respond-
ing 30 d after the lesion was calculated (Fig. 4 C). For the
digit 4 of control animals, 91% showed sensitivity (75% for
digit 5) compared with 80% for Tg16 (60% for digit 5)
and 25% for Tg11 (25% for digit 5) (Fig. 4 C). Thus, the
Nogo-A transgenic mice showed a significant delay in the re-
covery of the toe pinch reflex.
Spinal motoneurons were retrogradely labeled with Fluo-
rogold 7, 14, and 28 d after the crush from a site 7 mm dis-
tal to the lesion (Fig. 5, A and C). Fluorogold was chosen as
a marker because it is a long-lasting and nondiffusible tracer
that undergoes rapid retrograde axonal transport
 
.
 
 Nonle-
sioned transgenic mice had the same number of motoneu-
rons as wild-type mice. A time course with wild-type mice
was established to determine the time at which the trans-
genic animals were to be traced after the lesion. By 5 d, no
motoneuron axons had reached the injection site. Between 7
and 14 d, a gradual increase in the number of retrogradely
labeled motoneurons was seen and the peak number of mo-
toneurons was reached 17 d after the lesion. Therefore, 7
and 14 d after the lesion were chosen to analyze the motor
axonal regeneration, and a later time point (28 d) to analyze
axon numbers at a time when functional recovery in control
animals was complete. 7 and 14 d after a sciatic nerve lesion,
a significantly lower number of motor axons had grown 7
mm past the lesion in transgenic animals compared with
control animals (Fig. 5 B), indicating a slower regeneration
of the motoneuron axons. 28 d after the lesion, only a small
difference was noted in both transgenic groups compared
with the control group, indicating that almost all the axons
had reached the injection site. The discrepancy between this
last result and the behavioral data (Fig. 4) could be due to
the fact that 28 d after the lesion, most of the motoneuron
axons of the transgenic mice had reached the injection site 7
mm distal of the lesion but not the muscle target (
 
 
 
15 mm
away from the lesion), or not the appropriate target. Correct
locomotion is also dependent on regeneration and correct
targeting of sensory axons, which were not studied yet.
Finally, regenerating axons in the sciatic nerve were di-
rectly assessed using GAP-43 and neurofilament (SMI-32)
markers. GAP-43 stains mainly growing axons. SMI-32 rec-
ognizes nonphosphorylated neurofilaments, described as be-
ing more abundant than the phosphorylated form in regen-
erating axons of the lesioned sciatic nerve (Pestronk et al.,
1990; Tsuda et al., 2000). 7 d after the lesion, the labeled ax-
ons were counted on cross sections 4 mm distal to the lesion
on randomly photographed sections. In contrast to intact
nerves, most of these regenerating fibers were thin, fine cali-
Figure 4. Two independent Nogo-A transgenic mouse lines show a 
decrease in behavioral recovery after a sciatic nerve crush as 
compared with controls. (A) Recovery of locomotor function after 
sciatic nerve crush determined by the SFI. Nonlesioned animals have 
an SFI of zero. 28 d after the lesion, functional recovery was poor 
and the deficit long lasting in Tg11, delayed and incomplete in Tg16, 
and complete in the control mice. Means ( SEM) of control (Ctrl; 
n   10), line 16 (Tg16; n   5), and line 11 (Tg11; n   3) animals are 
shown. *, two-tailed Mann Whitney test, P   0.05 compared with 
controls. (B) Recovery of the toe pinch reflex is delayed in Tg11 and 
Tg16. Histogram shows the time in days after sciatic nerve crush at 
which initial toe pinch reflex was elicited for toe 3, toe 4, and toe 5. 
Mice from both lines show a delay in recovery, which is more 
pronounced in Tg11 than Tg16. The means ( SEM) of control (Ctrl; 
n   12), line 11 (Tg11; n   4), and line 16 (Tg16; n   5) animals are 
presented. *, two-tailed Mann Whitney test, P   0.05 compared 
with control. (C) Table of the distribution of animals that showed toe 
pinch reflex response 30 d after the operation. 
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ber fibers. Almost no debris was seen with those two mark-
ers. Compared with axon numbers of nonlesioned sciatic
nerves, regenerating nerves of control animals had 
 
 
 
40% of
the axons (unpublished data). A significantly lower axon
number was found in the regenerating sciatic nerves of the
transgenic animals using both markers (Fig. 5 D).
Taken together, these data show that postnatal expression
of Nogo-A in Schwann cells results in a significant delay in
 
axon regeneration in the denervated adult mouse sciatic
nerve. The selective postnatal expression prevented possible
effects of Nogo-A on the development of Schwann cells and
axons, or on the process of myelin formation. The doxycy-
cline treatment cannot be responsible for the observed dif-
ferences in regeneration because all the animals, controls and
transgenics, were treated with the drug. It is also unlikely
that the reporter 
 
lacZ
 
 had a negative effect because myelin
and Schwann cell morphology was normal, and, previously,
the reporter had been used in Schwann cells without any
signs of toxicity (Arroyo et al., 1998).
Efficient and successful regeneration in peripheral nerve is
influenced by Schwann cell–released neurotrophic factors,
extracellular matrix molecules, and basement membrane
components. The expression of Nogo-A slows down the rate
of axon growth compared with that seen in a normal dener-
vated sciatic nerve. The difference in the regenerative poten-
tial observed between the two 
 
nogo A
 
–expressing mouse lines
(Fig. 4) is probably related to their difference in expression
levels of 
 
nogo A
 
 (Fig. 2 B). 
 
P0
 
 promoter activity is also
known to be temporarily decreased distal to a lesion in the
context of Schwann cell dedifferentiation (Gupta et al.,
1988)
 
,
 
 thus possibly creating a window of increased oppor-
tunity for regenerating axons, although significant levels of
Nogo-A protein may still be present on myelin debris. 
 
P0
 
promoter is known to be strongly induced starting 7 d after
peripheral nerve lesion when the remyelination takes place
(Gupta et al., 1988), and thus could represent an impedi-
ment for late growing axons. All these data strongly indi-
cate that Nogo-A is a potent neurite growth inhibitor that
can override multiple strong regeneration-enhancing factors
known to be present in lesioned peripheral nerves.
Nogo-A, constitutively present in CNS myelin, biases the
balance of growth-promoting and -inhibitory factors toward
inhibition of regeneration, leading to a restriction of plastic-
ity and functional recovery. The inhibitory property of
Nogo-A is further demonstrated by enhanced regeneration,
compensatory sprouting, and functional recovery of lesioned
CNS tracts resulting from in vivo application of the mono-
clonal antibody IN-1 (Schnell and Schwab, 1990; Thallmair
et al., 1998; Merkler et al., 2001; Papadopoulos et al.,
2002). Similar results were obtained with autoantibodies
against myelin (Huang et al., 1999) and antibodies against
specific regions of the Nogo-A molecule (unpublished data).
All these results suggest that blockade of Nogo-A signaling
by antibodies, receptor-blocking reagents (GrandPre et al.,
2002), or drugs acting at the postreceptor level represent ex-
citing experimental approaches for therapies of CNS inju-
ries, including spinal cord or brain trauma and stroke.
 
Materials and methods
 
Plasmids for construction of the transgenic mice
 
For the generation of rtTA2-expressing mice, a 1.1-kb 
 
P0
 
 rat promoter fol-
lowed by a 350-bp portion of the human connexin 32 gene (30 bp of the
promoter, exon 1B, intron 1, and 20 bp of exon 2) was placed upstream of
the full-length 
 
rtTA2
 
 gene. A 
 
 
 
-globin transcription termination signal was
added to the 3
 
 
 
end. To generate the 
 
tet-O–nogo A–lacZ
 
 construct, a bidirec-
tional tetO promoter, consisting of a human cytomegalovirus minimal pro-
moter linked to the tet operator sequences was used. A 3.5-kb DNA frag-
ment encoding 
 
nogo A
 
 with myc and Xpress tags at the COOH terminus was
placed downstream of the tetO promoter in pBI-3 (Baron et al., 1995) (Fig. 1
Figure 5. Retrograde tracing and regenerating axons. (A) 7, 14, 
and 28 d after a sciatic nerve crush, the nerve was cut 7 mm distal 
to the lesion and crystals of the retrograde tracer Fluorogold were 
applied to the cut nerve. (B) 7 and 14 d after the lesion, the number 
of retrogradely labeled motoneurons is significantly smaller in the 
two transgenic lines (Tg11 and Tg16) compared with control 
animals, indicating a delay in axonal growth. 28 d after the lesion, 
no significant differences were seen; almost all the axons of the 
three mice groups had reached the injection site. *, unpaired 
two-tailed t test, P   0.05 compared with control. The means 
( SEM) are represented, n   5–8 in each group. (C) Sections 
through the ventral horn of the spinal cord show a smaller number 
of labeled motoneurons in Tg16 versus control (Ctrl) animals 14 d 
after the lesion. (D) Growing axons were directly labeled 4 mm 
distal to the lesion using antibodies against GAP-43 and the 
nonphosphorylated neurofilament marker SMI-32. Cross sections 
(top) were photographed at 630  and all the GAP-43–labeled 
axons were counted. Histograms (bottom) show the ratio of the 
axonal counts per section normalized to the highest count, setting 
the best animal at one. The animals from the transgenic group (Tg; 
n   6) show significantly less axons stained with GAP-43 or SMI-32 
than those from the control group (Ctr; n   5). The means ( SEM) 
are represented. *, unpaired two-tailed t test, P   0.05 compared 
with control. Bars: (C) 25  m; (D) 13  m.34 The Journal of Cell Biology | Volume 159, Number 1, 2002
A). Restriction fragments containing each transgene were isolated from vec-
tor sequences and prepared for microinjection into fertilized oocytes
Controlling the doxycycline-regulatable expression of nogo A 
in HeLa cells
HeLa cells, stably expressing the tTA construct, were transfected with pBI-
3-nogoA construct using FuGENE 6 transfection reagent (Roche). 3  g/ml
doxycycline solution was added to the culture medium for 24 h. The cells
were fixed for 15 min in 4% paraformaldehyde (PFA) and immunostained
for myc and Nogo-A, and the activity of  -galactosidase was assessed. For
 -galactosidase staining, the cells were incubated for 1 h at 37 C in a solu-
tion containing 1 mg/ml X-Gal (Roche), 5 mM potassium ferrocyanide, 5
mM potassium ferricyanide, 0.1% Triton X-100, and 2 mM MgCl2 in PBS.
For immunofluorescence, the cells were permeabilized with 0.1% Triton
X-100 in PBS and blocked with 10% FCS. Mouse anti-myc antibodies
(clone 9E10; Sigma-Aldrich) were incubated simultaneously with the rab-
bit anti–Nogo-A antiserum 472 (Chen et al., 2000) for 30 min at RT. Rabbit
antibodies were visualized by anti–rabbit FITC-conjugated secondary anti-
body, and mouse antibodies by anti–mouse TRITC-conjugated secondary
antibody (Jackson ImmunoResearch Laboratories).
Mouse breeding and genotyping
All transgenic lines were created using the hybrid strain B6D2F1. For both
constructs, founder lines were crossed for two to six generations into the
inbred strain C57BL/6. Double transgenic mice were obtained from
crosses between mice heterozygous for each transgene. The line with the
strongest expression of the transactivator (Tg-[P0Cx-rtTA2] 693 Zbz) and of
two independent reporter lines (Tg-[Nogo/LacZ] 728 and 732 Zbz) were
crossed, yielding the double transgenic lines Tg11 and Tg16. The geno-
types of the mice were determined by PCR analysis of genomic DNA iso-
lated from mouse tails. Primers 5 -CACGGCGGACAGAGCGTACAG-3 
and 5 -CCGAATTCACCATGTCTAGACTGG-3  were used to amplify a
600-bp fragment from the rtTA2 construct, and primers 5 -CCTGCTG-
CATCTGAGCCTGTG-3  (first exon of nogo A) and 5 -ACAGGTGCTAC-
TACTGACATCTG-3  (second exon of nogo A) to amplify a 548-bp frag-
ment from the cDNA for the tetO–nogo A construct. Transgene expression
was induced at birth by replacing normal drinking water with 5% sucrose
containing doxycycline (2 mg/ml). The mice were kept under doxycycline
until the end of the experiments.
Whole mount sciatic nerve preparation and 
immunofluorescence microscopy
Sciatic nerves of control and nogo A transgenic animals were dissected
and fixed by immersion in 4% PFA for 20 min on ice. For  -galactosidase
staining, the whole sciatic nerve was incubated overnight at 37 C in X-Gal
solution. After staining and photographing, the tissue was washed in PBS,
postfixed for 1 h in 4% PFA, and then frozen in the same block. Cryostat
sections (20  m) were cut. For immunofluorescence, the sections from
wild-type and transgenic animals were processed on the same slide by per-
meabilization with 0.03–0.3% Triton X-100 in PBS and blocked by 1%
BSA or 2% rat serum. Cy3-conjugated mouse anti-myc antibodies (clone
9E10; Sigma-Aldrich) were incubated simultaneously with a rabbit anti–
Nogo-A antiserum 472 or a rabbit anti-S100 antibody (Dako). The sections
were analyzed using a confocal ZEISS LSM 410 microscope or a ZEISS Ax-
iophot microscope equipped for epifluorescence.
Ultrastructural analysis
Mice were deeply anesthetized with pentobarbital and transcardially per-
fused by Ringer solution followed by 2% glutaraldehyde and 2% PFA in
0.1 M phosphate buffer. All fixative and buffer solutions were supple-
mented with 2 mM CaCl2. Sciatic nerves were removed, placed in fresh
fixative for 3 h, and then placed in cacodylate buffer overnight at 4 C. Tis-
sues were postfixed in 2% OsO4 for 2 h, serially dehydrated, and embed-
ded in Epon. Semi-thin sections were stained with toluidine blue and
viewed under an Olympus microscope. Ultrathin sections (90 nm) were
analyzed using a ZEISS EM 902.
Surgery
Mice (16–26 g) were deeply anesthetized by intraperitoneal injection of
fentanyl citrate (0.0189 mg/100 mg), fluanisone (0.6 mg/100 mg; Hyp-
norm; Jansen Biochemica), and midazolam (0.6 mg/100 mg; Dormicum;
Hoffmann-La Roche). The sciatic nerve was exposed in the upper thigh
and freeze crushed with watch-maker forceps that had been previously
cooled in liquid nitrogen for 30 s. The epineurium remained intact. The
crush site was marked with charcoal powder. The experiments were per-
formed in conformation with the Swiss animal protection laws and were
approved by the Cantonal Veterinary Department of Zurich.
Behavioral tests
Rotarod. Animals were tested for two consecutive days on a rotating rod;
the first day for the acceleration test and the second day for the fatigue test.
The acceleration test was performed by placing a mouse on the revolving
rod. Once balanced, the rod was accelerated from 4 to 40 rpm over a 300-s
period. The fatigue test was performed at a fixed speed of 40 rpm for 300 s.
For both tests, the latency for the mouse to fall off the rod was determined
with a cut-off of 300 s. The mice were given five trials with a 20-min rest
interval between each trial. The average time on the rod for each mouse
was used for analysis.
SFI.  After first pressing their hind paws onto an ink pad, the animals
were tested along a confined 60-cm-long walkway lined with plain white
paper. The tracks were analyzed according to the empirical equation de-
termined by de Medinaceli et al. (1982).
Toe pinch reflex.  Recovery of pain sensitivity was tested on awake mice
by lightly pinching the most distal portion of the last three digits of the le-
sioned hind limb with forceps. The first day after the lesion at which foot
withdrawal was restored was recorded.
Motoneuron tracing and histological analysis
Motoneurons tracing.  7, 14, and 28 d after surgery, crystals of Fluorogold
(Molecular Probes) were applied 7 mm distal to the crush lesion onto the
cut nerve. 48 h later, mice were deeply anesthetized with pentobarbital
and perfused with 4% PFA. Spinal cords were removed and processed for
cryosectioning as described by Sagot et al. (1998). Cryostat serial sections
(30  m) were viewed under fluorescence illumination, and Fluorogold-
labeled motoneurons, identified by size, shape, and location in the ventral
horn, were counted on every section.
Regenerating axons.  7 d after surgery, sciatic nerves were removed,
fixed as described above, and cut transversally 4 mm distal to the lesion.
After permeabilization with ethanol/acetic acid (95:5; 15 min), the sections
(15  m) were stained with a rabbit antiserum against GAP-43 (Chemicon)
or with a mice neurofilament antibody, SMI-32 (Sternberger Monoclonals
Inc.). Areas of 10  m
2 were randomly photographed from the two or three
fascicles of each nerve at 630 , and all labeled axons were counted by
two different, blinded observers.
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